Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Aquestive Therapeutics's Revenue for the
three
months ended in Jun. 2026 was $13.82 Mil. Aquestive Therapeutics's average Accounts Receivable for the
three
months ended in Jun. 2026 was $6.49 Mil.
Hence, Aquestive Therapeutics's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.13.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Aquestive Therapeutics Receivables Turnover Related Terms
Aquestive Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Aquestive Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQST vs TLRY, EOLS, IRWD: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aquestive Therapeutics (AQST) has a Receivables Turnover of 2.13 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aquestive Therapeutics and its competitors. According to the industry distribution chart, Aquestive Therapeutics ranks #282 out of 947 companies in the Drug Manufacturers industry, placing it in the top 29.8%.
Is Aquestive Therapeutics' Receivables Turnover too high?
Aquestive Therapeutics' current Receivables Turnover is 2.13. The Drug Manufacturers industry median Receivables Turnover is 5.08. Aquestive Therapeutics' value of 2.13 is 58.1% below this industry median. Based on the distribution chart, Aquestive Therapeutics ranks #282 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aquestive Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aquestive Therapeutics' Receivables Turnover compare to TLRY and EOLS?
According to the Drug Manufacturers industry distribution chart, Aquestive Therapeutics ranks #282 out of 947 companies for Receivables Turnover. This puts Aquestive Therapeutics in the upper half of its industry. The industry median Receivables Turnover is 5.08. Aquestive Therapeutics' value of 2.13 is 58.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aquestive Therapeutics's current Receivables Turnover of 2.13 is 58.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aquestive Therapeutics and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aquestive Therapeutics's current Receivables Turnover is 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquestive Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aquestive Therapeutics (AQST) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.37, compared to a current price of $5.16 — trading 117.7% above its estimated fair value. The current Receivables Turnover is 2.13 and 58.1% below the Drug Manufacturers industry median of 5.08. Aquestive Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Aquestive Therapeutics (AQST), the current Receivables Turnover is 2.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aquestive Therapeutics (AQST) Overvalued in 2026?
Based on GuruFocus' analysis, Aquestive Therapeutics stock appears to be overvalued.
The current stock price of $5.16 is trading 117.7% above its estimated GF Value™ of $2.37.
GuruFocus considers Aquestive Therapeutics to be Significantly Overvalued.
Key valuation signals for AQST:
Receivables Turnover: 2.13
GF Value™: $2.37 vs. price of $5.16 (117.7% above fair value)
Industry Position: 58.1% below the Drug Manufacturers median (#282 of 947)
No single metric tells the full story. See the AQST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
49GF Score
Get the complete analysis for AQST
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQST has been successfully added to your 
